Ablynx says blood disorder drug estimates conservative

November 21, 2014 1:45 PM

12 0

BRUSSELS (Reuters) - Belgian biotech company Ablynx believes its sales estimate for its drug for the rare blood disease TTP is conservative, after tests showed it had potential to treat more than just acute cases.

Ablynx recently raised its estimate for peak annual sales for the TTP candidate drug caplacizumab to 300-400 million euros ($373-497 million), from up to 250 million euros previously.

Read more

To category page